Ganoderma Spores Modulate the Gut-Brain Axis

NCT07524777 NA NOT_YET_RECRUITING

This study aims to investigate whether Sporoderm-removed Ganoderma lucidum spore powder (RGLS) ameliorates depression in thyroid cancer patients through gut-brain axis modulation, and to elucidate the underlying microbial and metabolic mechanisms. This 3-month randomized, double-blind, placebo-controlled trial will enroll 300 postoperative papillary thyroid carcinoma patients with depressive symptoms (HAMD-24 ≥ 8). Participants will be randomly assigned(2 : 1) to receive RGLS (2 g/day) or matched placebo.

Details

Lead sponsor	Ling Zhiqiang
Phase	NA
Status	NOT_YET_RECRUITING
Enrolment	300
Start date	Wed Apr 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Aug 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Depression
• Thyroid Cancer

Interventions

• Sporoderm-removed Ganoderma lucidum spore powder (RGLS)
• Placebo